HER-2-Negative Breast Cancer Limitations and Next-Generation Sequencing Technology Promises

ISSN： 1068-9265

Source： Annals of Surgical Oncology, Vol.17, Iss.6, 2010-06, pp. : 1720-1720

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Next-generation sequencing for lung cancer

By Wu Kehua Huang R Stephanie House Larry Cho William Chi

Future Oncology, Vol. 9, Iss. 9, 2013-09 ,pp. : 1323-1336

Future Medicine

Access to resources Recommend Favorite

Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing

The Oncologist, Vol. 23, Iss. 2, 2018-02 ,pp. : 179-185

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

By Perez Edith

Breast Cancer Research and Treatment, Vol. 121, Iss. 2, 2010-06 ,pp. : 261-271

Springer Publishing Company

Access to resources Recommend Favorite

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance

By Dua Rajiv

Breast Cancer Research and Treatment, Vol. 122, Iss. 3, 2010-08 ,pp. : 685-697

Springer Publishing Company

Access to resources Recommend Favorite

Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients

International Journal of Oncology, Vol. 45, Iss. 6, 2014-01 ,pp. : 2549-2559

Spandidos Publications

Access to resources Recommend Favorite